Australia's most trusted
source of pharma news
Posted 22 October 2025 AM
AstraZeneca hopes its antibody drug conjugate (ADC) Enhertu will become a foundational treatment for early stage breast cancer after delivering significant results in Phase 3 trials.
In the DESTINY-Breast11 trial, which assessed Enhertu in the neoadjuvant setting, about 67 per cent of patients with high-risk HER2-positive early-stage breast cancer achieved a pathological complete response (no evidence of invasive cancer in the breast tissue or lymph nodes) after being treated with Enhertu followed by a chemotherapy and HER2-targeting therapy regimen of Taxol, Herceptin and Perjeta (THP).
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.